In this randomized controlled trial, among patients with atrial fibrillation requiring anticoagulation therapy, asundexian ...

In this randomized controlled trial, abelacimab led to significantly lower rates of major or clinically relevant nonmajor ...

Discover how botanical and nutrient therapies provided adjunctive support for a 76-year-old patient with treatment-resistant ...

Atrial fibrillation is a cardiac arrhythmia in which the upper chambers of the heart the atria beat irregularly and, often, rapidly. The condition occurs as a consequence of uncoordinated ...

Atrial fibrillation (AF) is the most common sustained arrhythmia worldwide ... The use of preprocedural transesophageal echocardiography to rule out intracardiac thrombus was according to expert ...

Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation ... cancer patients at risk of thrombosis in its MAGNOLIA and ...

Psoriasis is linked to an increased risk of atrial fibrillation (AF). However, data on the electrophysiological substrate and outcomes of AF ablation in patients with psoriasis are lacking. We ...

Height is one of the most noticeable physical traits and is shaped by both genetics and environment. Nutrition, socioeconomic ...

The clock is, once again, going ahead by an hour. While "springing forward" might seem easy, it's a good idea to know the ...

The FDA approved the first generics of the direct oral anticoagulant rivaroxaban, the agency announced on Tuesday.

Ten projects at Queen’s are receiving support from the Canadian Institutes of Health Research to advance research that will have a high impact on health care knowledge and delivery.

5 Université Jean-Monnet, UMR 1059, SAINBIOSE; INSERM CIC 1408, Saint-Étienne, France Background The prevalence of venous thromboembolic event (VTE) and arterial thromboembolic event (ATE) ...